STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer

被引：30

作者：

Attili, Ilaria ^{[1
]}

Karachaliou, Niki ^{[2
,3
]}

Bonanno, Laura ^{[4
]}

Berenguer, Jordi ^{[2
]}

Bracht, Jillian ^{[2
]}

Codony-Servat, Jordi ^{[2
]}

Codony-Servat, Carles ^{[2
]}

Ito, Masaoki ^{[2
,5
]}

Rosell, Rafael ^{[2
,6
,7
,8
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Via Giustiniani 2,53, I-35128 Padua, Italy

[2] Quiron Dexeus Univ Inst, Coyote Res Grp, Lab Mol Biol, Pangaea Oncol, Barcelona, Spain

[3] Univ Hosp Sagrat Cor, Inst Oncol Dr Rosell IOR, Barcelona, Spain

[4] IRCCS, Ist Oncol Veneto, Padua, Italy

[5] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan

[6] Quiron Dexeus Univ Inst, Inst Oncol Dr Rosell IOR, Barcelona, Spain

[7] Inst Invest Ciencies Germans Trias & Pujol, Badalona, Spain

[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2018年 / 10卷

关键词：

biomarkers; immunotherapy; lung cancer; PD-L1; STAT3; NF-KAPPA-B; PD-L1; EXPRESSION; OPEN-LABEL; SERINE PHOSPHORYLATION; DENDRITIC CELLS; ACTIVATION; INHIBITION; RESISTANT; DOCETAXEL; NIVOLUMAB;

D O I：

10.1177/1758835918763744

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the microenvironment is limited, preventing the optimal use of these new compounds and the maximum benefit that the patients can derive from them. We have actively worked on the role of STAT3, a transcriptional factor that causes innate resistance to targeted therapies in oncogene-addicted tumors. In this short review we take the opportunity to express our opinion and review existing knowledge on the immune role of STAT3 and the possible implications that this may have for the discovery of new biomarkers to predict response to immunotherapy, as well as new partners to combine with and increase the efficacy of immune checkpoint inhibitors.

引用

页数：9

共 85 条

[1] AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells [J].

Abdelhamed, Sherif ;

Ogura, Keisuke ;

Yokoyama, Satoru ;

Saiki, Ikuo ;

Hayakawa, Yoshihiro .

JOURNAL OF CANCER, 2016, 7 (12) :1579-1586

[2]

[Anonymous], ANN ONCOL

[3] Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs? [J].

Attili, Ilaria ;

Passaro, Antonio ;

Pavan, Alberto ;

Conte, PierFranco ;

De Marinis, Filippo ;

Bonanno, Laura .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 119 :30-39

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[6] CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity [J].

Burr, Marian L. ;

Sparbier, Christina E. ;

Chan, Yih-Chih ;

Williamson, James C. ;

Woods, Katherine ;

Beavis, Paul A. ;

Lam, Enid Y. N. ;

Henderson, Melissa A. ;

Bell, Charles C. ;

Stolzenburg, Sabine ;

Gilan, Omer ;

Bloor, Stuart ;

Noori, Tahereh ;

Morgens, David W. ;

Bassik, Michael C. ;

Neeson, Paul J. ;

Behren, Andreas ;

Darcy, Phillip K. ;

Dawson, Sarah-Jane ;

Voskoboinik, Ilia ;

Trapani, Joseph A. ;

Cebon, Jonathan ;

Lehner, Paul J. ;

Dawson, Mark A. .

NATURE, 2017, 549 (7670) :101-105

[7]

Chae YK, ONCOLOGIST, DOI [10.1634/, DOI 10.1634/]

[8] Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC [J].

Chaib, Imane ;

Karachaliou, Niki ;

Pilotto, Sara ;

Codony Servat, Jordi ;

Cai, Xueting ;

Li, Xuefei ;

Drozdowskyj, Ana ;

Codony Servat, Carles ;

Yang, Jie ;

Hu, Chunping ;

Felipe Cardona, Andres ;

Vivanco, Guillermo Lopez ;

Vergnenegre, Alain ;

Miguel Sanchez, Jose ;

Provencio, Mariano ;

de Marinis, Filippo ;

Passaro, Antonio ;

Carcereny, Enric ;

Reguart, Noemi ;

Garcia Campelo, Charo ;

Teixido, Cristina ;

Sperduti, Isabella ;

Rodriguez, Sonia ;

Lazzari, Chiara ;

Verlicchi, Alberto ;

de Aguirre, Itziar ;

Queralt, Cristina ;

Wei, Jia ;

Estrada, Roger ;

Puig de la Bellacasa, Raimon ;

Luis Ramirez, Jose ;

Jacobsen, Kirstine ;

Ditzel, Henrik J. ;

Santarpia, Mariacarmela ;

Viteri, Santiago ;

Angel Molina, Miguel ;

Zhou, Caicun ;

Cao, Peng ;

Ma, Patrick C. ;

Bivona, Trever G. ;

Rosell, Rafael .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (09)

[9] Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J].

Chen, Nan ;

Fang, Wenfeng ;

Zhan, Jianhua ;

Hong, Shaodong ;

Tang, Yanna ;

Kang, Shiyang ;

Zhang, Yaxiong ;

He, Xiaobo ;

Zhou, Ting ;

Qin, Tao ;

Huang, Yan ;

Yi, Xianping ;

Zhang, Li .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :910-923

[10] Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC) [J].

Codony-Servat, Carles ;

Codony-Servat, Jordi ;

Karachaliou, Niki ;

Angel Molina, Miguel ;

Chaib, Imane ;

Luis Ramirez, Jose ;

de los Llanos Gil, Maria ;

Solca, Flavio ;

Bivona, Trever G. ;

Rosell, Rafael .

ONCOTARGET, 2017, 8 (29) :47305-47316

← 1 2 3 4 5 6 7 8 9 →